FibroBiologics, Inc. Common Stock

FibroBiologics has closed a $0.5 million private placement with its Chief Scientific Officer, Hamid Khoja. The clinical-stage biotechnology company sold 298,508 shares of common stock and accompanying warrants to purchase up to 298,508 shares of common stock, priced at-the-market under Nasdaq rules. Each share and accompanying warrant was sold at a combined purchase price of $1.675, equal to the consolidated closing bid price of $1.55 per share on The Nasdaq Capital Market on September 14, 2026, plus $0.125 per warrant. The warrants have an exercise price of $1.55 per share, are immediately exercisable, and expire five years from issuance. FibroBiologics received gross proceeds of approximately $0.5 million before deducting offering expenses and intends to use the net proceeds for general corporate purposes and working capital. Chief Executive Officer Pete O'Heeron said Dr. Khoja is the scientific architect of the company's platform and that his decision to increase his investment as a shareholder speaks for itself, while Dr. Khoja said investing in FibroBiologics is his personal commitment to the science, the team, and the potential therapeutics being developed.

FibroBiologics has received a notice of allowance from the US Patent and Trademark Office for a patent application covering its topical fibroblast spheroid therapy for wound healing. The allowed application, number 18/184,726, contains 19 claims directed to methods of treating and accelerating wound healing by topically administering three-dimensional spheroid fibroblasts, alone or with fibroblast-derived materials. The claims specifically encompass treatment of chronic wounds and individuals with diabetes, aligning with the company’s lead program CYWC628, an investigational allogeneic fibroblast-spheroid cell-based therapy currently in a Phase 1/2 clinical trial for diabetic foot ulcers. Founder and CEO Pete O’Heeron said the notice protects the approach being advanced in the clinic and strengthens the company’s competitive position. Chief Scientific Officer Hamid Khoja noted the examiner recognized the combination of 3D spheroid fibroblasts with or without fibroblast-derived materials as not taught by prior art, providing a strong intellectual property foundation as clinical data are generated.